

# Thai Huu Ho

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7192259/thai-huu-ho-publications-by-year.pdf>

**Version:** 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

70  
papers

5,716  
citations

30  
h-index

75  
g-index

79  
ext. papers

7,331  
ext. citations

9  
avg, IF

4.86  
L-index

#	Paper	IF	Citations
70	MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers.. <i>Nature Communications</i> , <b>2022</b> , 13, 1797	17.4	0
69	MicroRNA Expression in Clear Cell Renal Cell Carcinoma Cell Lines and Tumor Biopsies: Potential Therapeutic Targets. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23, 5604	6.3	
68	Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR). <i>Oncologist</i> , <b>2021</b> , 26, 560-e1103	5.7	1
67	Outcome prediction following radical nephroureterectomy for upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 133.e9-133.e16	2.8	0
66	Identification of DNA methylation signatures associated with poor outcome in lower-risk Stage, Size, Grade and Necrosis (SSIGN) score clear cell renal cell cancer. <i>Clinical Epigenetics</i> , <b>2021</b> , 13, 12	7.7	3
65	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. <i>Nature Communications</i> , <b>2021</b> , 12, 808	17.4	26
64	ZMYND8 preferentially binds phosphorylated EZH2 to promote a PRC2-dependent to -independent function switch in hypoxia-inducible factor-activated cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2021</b> , 118,	11.5	2
63	Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2021</b> ,	6.2	1
62	Phase Ib Study of Atezolizumab Plus Interferon- $\gamma$ with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors.. <i>Current Oncology</i> , <b>2021</b> , 28, 5466-5479	2.8	0
61	8q24 clear cell renal cell carcinoma germline variant is associated with VHL mutation status and clinical aggressiveness. <i>BMC Urology</i> , <b>2020</b> , 20, 173	2.2	1
60	Macrophage HIF-1 $\alpha$ is an Independent Prognostic Indicator in Kidney Cancer. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 4970-4982	12.9	11
59	Lgr5-positive endothelial progenitor cells occupy a tumor and injury prone niche in the kidney vasa recta. <i>Stem Cell Research</i> , <b>2020</b> , 46, 101849	1.6	2
58	Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers. <i>Scientific Reports</i> , <b>2020</b> , 10, 701	4.9	13
57	Evolving Natural History of Metastatic Prostate Cancer. <i>Cureus</i> , <b>2020</b> , 12, e11484	1.2	1
56	Concordance of PD-1 and PD-L1 (B7-H1) in paired primary and metastatic clear cell renal cell carcinoma. <i>Cancer Medicine</i> , <b>2020</b> , 9, 1152-1160	4.8	9
55	Molecular Inhibitor of QSOX1 Suppresses Tumor Growth. <i>Molecular Cancer Therapeutics</i> , <b>2020</b> , 19, 112-122	10.2	6
54	In silico DNA methylation analysis identifies potential prognostic biomarkers in type 2 papillary renal cell carcinoma. <i>Cancer Medicine</i> , <b>2019</b> , 8, 5760-5768	4.8	3

53	Loss of SETD2 Induces a Metabolic Switch in Renal Cell Carcinoma Cell Lines toward Enhanced Oxidative Phosphorylation. <i>Journal of Proteome Research</i> , <b>2019</b> , 18, 331-340	5.6	16
52	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. <i>Cell Reports</i> , <b>2018</b> , 23, 313-326.e5	10.6	295
51	Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. <i>Science</i> , <b>2018</b> , 359, 801-806	33.3	562
50	Behavior of blood plasma glycan features in bladder cancer. <i>PLoS ONE</i> , <b>2018</b> , 13, e0201208	3.7	12
49	Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 5250-5260	12.9	65
48	The Impact of Pazopanib on the Cardiovascular System. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , <b>2018</b> , 23, 387-398	2.6	12
47	Pazopanib for renal cell carcinoma leads to elevated mean arterial pressures in a murine model. <i>Clinical and Experimental Hypertension</i> , <b>2018</b> , 40, 524-533	2.2	3
46	Chromosome 3p Loss-Orchestrated VHL, HIF, and Epigenetic Deregulation in Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , <b>2018</b> , JCO2018792549	2.2	52
45	Stage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, $\alpha$ -4 Branching, $\alpha$ -6 Branching, and $\alpha$ -6 Sialylation in Cancer. <i>Journal of Proteome Research</i> , <b>2018</b> , 17, 543-558	5.6	14
44	Comprehensive Genomic Analysis of Metastatic Mucinous Urethral Adenocarcinoma Guides Precision Oncology Treatment: Targetable EGFR Amplification Leading to Successful Treatment With Erlotinib. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, e727-e734	3.3	1
43	Clear Cell Type A and B Molecular Subtypes in Metastatic Clear Cell Renal Cell Carcinoma: Tumor Heterogeneity and Aggressiveness. <i>European Urology</i> , <b>2017</b> , 71, 979-985	10.2	37
42	Factors Associated With Survival Following Radium-223 Treatment for Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, e969-e975	3.3	35
41	Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. <i>Cell</i> , <b>2017</b> , 171, 540-556.e25	9.2	961
40	Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3706-3713	2.2	25
39	Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development. <i>Cardio-Oncology</i> , <b>2017</b> , 3,	2.8	16
38	BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor. <i>BMC Urology</i> , <b>2017</b> , 17, 19	2.2	15
37	A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, 196-202.e1	3.3	6
36	Inhibition of intracellular lipolysis promotes human cancer cell adaptation to hypoxia. <i>ELife</i> , <b>2017</b> , 6,	8.9	68

35	Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression. <i>Journal of Urology</i> , <b>2016</b> , 195, 180-7	2.5	85
34	Detection of tumor-associated cells in cryopreserved peripheral blood mononuclear cell samples for retrospective analysis. <i>Journal of Translational Medicine</i> , <b>2016</b> , 14, 198	8.5	10
33	Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2016</b> , 14, 820-4	7.3	26
32	Clinical Implementation of Integrated Genomic Profiling in Patients with Advanced Cancers. <i>Scientific Reports</i> , <b>2016</b> , 6, 25	4.9	20
31	Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. <i>Cell Reports</i> , <b>2016</b> , 14, 2476-89	10.6	228
30	DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 6236-6246	12.9	30
29	Predictors of incipient dysfunction of all cardiac chambers after treatment of metastatic renal cell carcinoma by tyrosine kinase inhibitors. <i>Journal of Clinical Ultrasound</i> , <b>2016</b> , 44, 221-30	1	4
28	Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response. <i>European Urology Focus</i> , <b>2016</b> , 2, 204-209	5.1	30
27	Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 2445-2452	12.9	150
26	Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death. <i>Modern Pathology</i> , <b>2016</b> , 29, 34-42	9.8	40
25	Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 135-45	59.2	753
24	Dynamic reprogramming of DNA methylation in SETD2-deregulated renal cell carcinoma. <i>Oncotarget</i> , <b>2016</b> , 7, 1927-46	3.3	36
23	The histone H3.3K36M mutation reprograms the epigenome of chondroblastomas. <i>Science</i> , <b>2016</b> , 352, 1344-8	33.3	151
22	Validation of Gene Expression Signatures to Identify Low-risk Clear-cell Renal Cell Carcinoma Patients at Higher Risk for Disease-related Death. <i>European Urology Focus</i> , <b>2016</b> , 2, 608-615	5.1	4
21	Dual Chromatin and Cytoskeletal Remodeling by SETD2. <i>Cell</i> , <b>2016</b> , 166, 950-962	56.2	128
20	Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 1071-7	12.9	173
19	PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation. <i>Cancer Immunology Research</i> , <b>2015</b> , 3, 1303-7	12.5	106
18	Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2015</b> , 33, 23.e9-23.e14	2.8	31

17	Hypoxia-induced SUMOylation of E3 ligase HAF determines specific activation of HIF2 in clear-cell renal cell carcinoma. <i>Cancer Research</i> , <b>2015</b> , 75, 316-29	10.1	26
16	Assessing the clinical use of clear cell renal cell carcinoma molecular subtypes identified by RNA expression analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2015</b> , 33, 68.e17-23	2.8	10
15	A Multidisciplinary Biospecimen Bank of Renal Cell Carcinomas Compatible with Discovery Platforms at Mayo Clinic, Scottsdale, Arizona. <i>PLoS ONE</i> , <b>2015</b> , 10, e0132831	3.7	8
14	The impact of FGFR1 and FRS2 expression on sorafenib treatment in metastatic renal cell carcinoma. <i>BMC Cancer</i> , <b>2015</b> , 15, 304	4.8	13
13	Ebselen inhibits QSOX1 enzymatic activity and suppresses invasion of pancreatic and renal cancer cell lines. <i>Oncotarget</i> , <b>2015</b> , 6, 18418-28	3.3	37
12	Sporadic RCC: Abnormalities in Histone-Modifying Genes <b>2015</b> , 153-165		
11	Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects. <i>Genome Research</i> , <b>2014</b> , 24, 241-50	9.7	124
10	Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma. <i>Cancer</i> , <b>2014</b> , 120, 1059-67	6.4	100
9	Distinct and overlapping control of 5-methylcytosine and 5-hydroxymethylcytosine by the TET proteins in human cancer cells. <i>Genome Biology</i> , <b>2014</b> , 15, R81	18.3	72
8	Genetic kidney cancer syndromes. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2014</b> , 12, 1347-55	7.3	19
7	Inverse association between programmed death ligand 1 and genes in the VEGF pathway in primary clear cell renal cell carcinoma. <i>Cancer Immunology Research</i> , <b>2013</b> , 1, 378-85	12.5	31
6	Axitinib in the treatment of metastatic renal cell carcinoma. <i>Future Oncology</i> , <b>2011</b> , 7, 1247-53	3.6	27
5	Transgenic mice expressing CUG-BP1 reproduce splicing mis-regulation observed in myotonic dystrophy. <i>Human Molecular Genetics</i> , <b>2005</b> , 14, 1539-47	5.6	202
4	Colocalization of muscleblind with RNA foci is separable from mis-regulation of alternative splicing in myotonic dystrophy. <i>Journal of Cell Science</i> , <b>2005</b> , 118, 2923-33	5.3	157
3	Muscleblind proteins regulate alternative splicing. <i>EMBO Journal</i> , <b>2004</b> , 23, 3103-12	13	369
2	Simple mimetics of a nuclear localization signal (NLS). <i>Organic Letters</i> , <b>2003</b> , 5, 2437-40	6.2	6
1	The mechanism of inhibition of Ran-dependent nuclear transport by cellular ATP depletion. <i>Journal of Cell Biology</i> , <b>2002</b> , 157, 963-74	7.3	105